Infection Risk Declined After Six Months of Linvoseltamab
Patients with multiple myeloma saw infection rates stabilize and decrease during long-term treatment with the drug.
Updated on Oct. 1, 2026 in Cancer
A study of 117 patients receiving linvoseltamab for multiple myeloma found that while infection risks were significant during the early stages of therapy, they decreased after six months. This longitudinal analysis provides important context for those managing infection concerns during ongoing cancer treatment.
Why it matters
Patients with multiple myeloma face an inherently higher risk of infection, making the timing of these events critical for clinical planning. Understanding that risks shift over the course of treatment allows patients and physicians to better anticipate and manage these complications.
In a study of 117 multiple myeloma patients followed for a median of 14.3 months, 74.4% reported infections, with 45.3% experiencing Grade 3 or higher events. Infection resolution occurred in a median of 14 days, with rates dropping notably after the first six months of therapy.
The details
Linvoseltamab is a treatment for multiple myeloma, a cancer that affects the immune system's plasma cells. To mitigate the risk of infection during treatment, participants followed a protocol that included PJP prophylaxis, antiviral medications, and immunoglobulin replacement therapy. The study utilized a post hoc exploratory landmark analysis to track how infection rates changed as patients progressed through their treatment regimen.
Timeline
During the first 6 months, patients experienced higher infection rates.
After 6 months, infection event rates declined and stabilized.
Health Landscape
This analysis of infection patterns in the LINKER-MM1 clinical study provides updated safety data regarding immunotherapy for plasma cell disorders. It contributes to the evolving understanding of how long-term management affects patient immune health in the context of newer targeted therapies.
If you are currently undergoing treatment for multiple myeloma, it is worth discussing infection risks and prophylaxis protocols with your oncology team. Understanding that certain side effects may stabilize over time can help you better manage your long-term treatment plan.
The takeaway
While infection remains a significant clinical challenge during multiple myeloma therapy, risk profiles may shift as treatment progresses. Always coordinate with your physician to ensure you are following the most effective preventative measures for your specific health needs.
Further reading
For more on how cancer treatments intersect with immune health, see our latest research in Cancer.
Source note: This article includes information reported by Nature.
